The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions

British Journal of Ophthalmology

Volumn 95, Issue 12, 2011, Pages 1682-1685

  Cannon, Paul S ^a   O'Donnell, Brett ^b   Huilgol, Shyamala C ^a   Selva, Dinesh ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMIQUIMOD; STEROID;

ACTINIC KERATOSIS; ADULT; ADVERSE OUTCOME; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE REACTION; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CELLULITIS; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EYE CANCER; EYE IRRITATION; FEMALE; HUMAN; KERATITIS; LOWER EYELID; MALE; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CONJUNCTIVITIS; ERYTHEMA; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 81555198385     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.178202     Document Type: Article

References (18)

1. Gupta AK, Browne M, Bluhm R. Imiquimod: a review. J Cutan Med Surg 2002;6:554-60. (Pubitemid 36091502)
2. Lacarrubba F, Nasca MR, Micali G. Advances in the user of topical imiquimod to treat dermatologic disorders. Ther Clin Risk Manag 2008;4:87-97. (Pubitemid 351460934)
3. Marks R, Bebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13. (Pubitemid 32391169)
4. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomised, vehicle-controlled studies. Am Acad Dermatol 2004;50:722-33. (Pubitemid 38580549)
5. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol 2002;138:1165-71. (Pubitemid 35025688)
6. Huber A, Huber JD, Skinner RB, et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 2004;30:429-30. (Pubitemid 38524166)
7. Miller R. Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Int J Dermatol 2002;41:3-6.
8. Richwald GA. Imiquimod. Drugs Today (Barc) 1999;35:497-511. (Pubitemid 29422126)
9. Drummer R, Urosevic M, Kempf W, et al. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2002;149:57-8.
10. Dahl MV. Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002;47:205-8.
11. Majewski S, Marczak M, Mlynarczyk B, et al. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005;44:14-19. (Pubitemid 40201982)
12. Leppala J, Kaarniranta K, Uusitalo H, et al. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007;85:566-8. (Pubitemid 47163120)
13. Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol 2005;140:1136-9. (Pubitemid 41821311)
14. Choontanom R, Thanos S, Busse H, et al. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007;245:1217-20. (Pubitemid 47034345)
15. Murchison AP, Washington CV, Soloman AR, et al. Ocular effects of imiquimod with treatment of eyelid melanoma in situ. Dermatol Surg 2007;33:1076-138.
16. Tsang HH, Huynh NT, Hollenbach E. Topical therapy with imiquimod for eyelid lesion. Clin Exp Ophthalmol 2006;34:179-81. (Pubitemid 43348995)
17. Brannan PA, Anderson HK, Kersten RC, et al. Bowen disease of the eyelid successfully treated with imiquimod. Ophthalmol Plast Reconstr Surg 2005;21:321-2. (Pubitemid 41099853)
18. Garland SM. Imiquimod. Curr Opin Infect Dis 2003;16:85-9. (Pubitemid 36521020)